ūüéČ Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application

Dear mental healthcare professionals,

A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence. Caring for others can be exhausting, and taking care of yourself through these challenging times requires intentional steps of self-care.
As the world emerges from a pandemic, the likes of which has not been experienced in many generations, the tsunami of mental health challenges has only increased. The spike in mental healthcare needs has created a shortage of therapy providers, and thus, you are each being asked to do more than ever. Despite these realities, you still show up every day to help where you can.

As an advocate for mental health and wellness for everyone, we care about your well-being. You are the ones that care for other people; as such, it is just as important to address your health and wellness as it is to address those who depend on you for their health and well-being.

ATMA is in the mental wellness business by means of the therapeutic use of psychedelic medicine; sometimes the significance of this work can get lost in the details of running a business. However, last weekend, as we administered psilocybin medicine to fourteen healthcare workers in the first cohort of a clinical trial, it was a reminder of the importance of your mental and spiritual health. A huge measure of our success is related to the improvements we can make in the lives and practices of mental healthcare providers.

Thank you for the work you are doing to help our world make it through these tough times. If you can take a moment, please share with us both your current struggles and successes so that we can better understand how we can serve you in our offerings.

David Harder

Click here to share your story!


More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

This trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB,¬†Sept. 14, 2022¬†/CNW/ –¬†ATMA Journey Centers Inc.¬†(“ATMA”), an¬†Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin

Psychedelic Breakthrough

Breakthroughs in the Therapy Room – Hope for Treatment Resistant Mental Illness?

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner ¬† The Role of Psychedelics in Therapeutic Breakthroughs One of the main goals of psychotherapy is to guide patients toward therapeuticbreakthroughs ‚Äď defined as a significant, sometimes sudden, step forward or important realization. Oftentimes, in therapy, breakthroughs come after long, unproductive plateaus. Such realizations must come from

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  ‚Äď Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 ‚ÄĒ‚ÄĮATMA Journey Centers (the ‚ÄúCompany‚ÄĚ), a company providing therapist training and support, has

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Scroll to Top